Skip to main content
. 2022 Dec 20;12:1084683. doi: 10.3389/fonc.2022.1084683

Figure 4.

Figure 4

Impact of 1q gain and its accompanying chromosomal abnormalities on the survival of patients with myeloma. (A). Progression-free survival (PFS) was significantly longer when comparing the FISH-negative group with the other abnormalities group and the +1q and other abnormalities group, respectively, but there was no significant difference with the +1q group. (B). Compared with the fluorescence in situ hybridization (FISH)-negative group, only the other abnormality group, showed a significant difference in overall survival (OS).